IICT, Lee Pharma ink licensing agreement for synthesis of 2-Deoxy-D-Glucose
IICT, Lee Pharma ink licensing agreement for synthesis of 2-Deoxy-D-Glucose
09 June 2021 | News Lee Pharma will manufacture and commercialise the 2-DG sachets from their formulation facility located at SEZ, Duvvada
Image Credit: Twitter
Indian Institute of Chemical Technology, (IICT), a constituent laboratory of CSIR and Lee Pharma, an integrated pharmaceutical company, based in Hyderabad have entered into a non-exclusive licensing agreement for the synthesis of 2-Deoxy-D-Glucose (2-DG).
Recently, 2-DG developed by DRDO and Dr Reddy’s Laboratories has received approval for use in COVID-19 patients. It has been found to help speed up recovery and reduce oxygen dependence and Dr Reddy’s Laboratories has launched the drug in the form of sachets.
Niclosamide has been extensively used in the past for treatment of tapeworm s infection in adults as well as children and its safety profile has been tested over time.
The curious case of Covaxin royalties downtoearth.org.in - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from downtoearth.org.in Daily Mail and Mail on Sunday newspapers.
Express News Service
HYDERABAD: Hyderabad-based Centre for Cellular and Molecular Biology (CCMB), along with the Indian Institute of Chemical Technology (IICT), is collecting samples from various water bodies in the city to find out how many people are affected by Covid-19 and whose load is more for which virus variant. They are carrying out the study based on wastewater-based epidemiology (WBE).
During the first wave in August last year, the two institutions published a part of the ongoing study based on samples they had collected from different water bodies in the city, including Hussainsagar, Pedda Cheruvu (in Nacharam) and Nizam Talab.